Mts1/cdk4i is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma
- W. Andrew Yeudall(corresponding author),
- Rosalynn Y. Crawford,
- John Ensley,
- Keith Robbins
- National Institutes of Health,
- Laboratory of Cellular,
- Wayne State University
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
The MTS1/CDK4I gene encodes a 16 kDa cyclin kinase inhibitor and maps to chromosome 9p21. Previous studies have suggested the presence of a major tumour suppressor gene at this locus which may be inactivated in head and neck squamous cell carcinoma (HNSCC). To determine the status of this gene in human primary and metastatic HNSCC, we examined the locus and its transcript for abnormalities by polyroerase chain reaction (PCR). Out of 14 cell lines studied, four had lost only exon 1, one had lost only exon 2, three had lost both exons 1 and 2, and none of the remaining six lines expressed a normal pl6 mRNA. These latter six cell lines expressed pl6 transcripts that had suffered deletions ranging in size from 2-16 base pairs. In each case, deletionsled to a change of reading frame. Furthermore, in two cases abnormalities in the MTS1/CDK4I gene were identical in cells derived from metastatic tumours as compared to cells derived independently from the corresponding primary tumour. The identical nature of mutations observed in primary tumours and metastases derived from the same patient provides strong evidence thatinactivation of pl6 function was an in vivo event Introduction Mutations affecting genes whose
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 2683-2686 (4 pages)Journal (Volume, Issue Number)
Carcinogenesis (Volume 15, Issue 12)Publication milestones
- Published - 12/1994
Publication status
ISSN
0143-3334Publication IDs
- Scopus: 0028566272
- PubMed: 8001221
